They Knew What They Were Walking Into: Why the Era of Buying a Dental Practice on Faith Is Ending

I recently had a conversation with a veteran broker. He has facilitated hundreds of practice sales. He has seen every variation of the deal — the good, the bad, and the ones that end up in litigation. He referred a practice to me earlier this year, and after we completed the buyer-side evaluation, I sent him the final report so he could see the level of detail we were working with.

His response was telling. He said he had never seen a more thorough deep dive into a practice.

Consider what that statement means coming from someone in his position. This is a person who has been in the room for hundreds of transactions. He has seen the lender’s underwriting packages, the CPA’s tax analysis, the attorney’s purchase agreement review. He has watched buyers and sellers negotiate, close, and transition. He has seen the full range of how these deals get done.

What he had almost never seen was a true operational forensic evaluation from the buyer’s side. Not a financial review. Not a lender’s cash flow analysis. A ground-level, data-driven assessment of how the practice actually runs — the clinical production mix, the case acceptance reality, the fee schedule exposure, the team dynamics, the gap between what the numbers claim and what the practice management software actually shows.

He wasn’t saying that to flatter me. He was stating a fact about the industry. The bar for buyer-side due diligence in dental transitions is staggeringly low. Most buyers look at the tax returns, check the age of the equipment, secure the loan, and sign the papers.

But this broker recognized something else. He knew that the buyer we were representing wasn’t just avoiding a bad deal.

He knew that they knew exactly what they were walking into.

---

The End of the Faith-Based Acquisition

For decades, buying a dental practice was largely a faith-based exercise. You trusted the broker’s prospectus. You trusted the seller’s narrative. You trusted that the active patient count was accurate, that the hygiene program was healthy, and that the revenue would hold once the seller walked out the door.

You made a million-dollar investment without ever really looking under the hood.

Couldn’t be me.

And increasingly, it isn’t the next generation of buyers, either. The market is shifting. Buyers are becoming more intelligent, more analytical, and far more protective of their capital. They are realizing that lender underwriting is not operational due diligence. The bank only cares if the historical cash flow can service the debt. The bank does not care if the practice’s case acceptance rate is 41% instead of the 77% claimed on the dashboard. The bank does not care if the seller’s Delta Premier status creates a 30% revenue cliff the moment the new owner takes over.

The smartest buyers are no longer willing to fly blind. They are demanding data. And sellers who refuse to provide it are starting to find that the market is far less forgiving than it used to be.

---

What the Prospectus Doesn’t Tell You

The broker’s prospectus is a marketing document. That is not a criticism — it is simply what it is. Its job is to present the practice in the most favorable light, attract qualified buyers, and generate offers. It is not designed to surface operational risk. It is not designed to identify value gaps. And it is certainly not designed to tell you what the practice will look like on Day 1 after the seller leaves.

Here is what the prospectus almost never tells you:

The Production Story: A practice generating $1.2 million in collections sounds strong. But if 65% of that production is tied to a single provider who is leaving, the revenue is not transferable. The prospectus shows you the top line. It does not show you how fragile the foundation is.

The Real Case Acceptance Rate: Practice management software is only as accurate as the data entry standards behind it. When a front desk associate marks a treatment plan as “accepted” on a verbal yes — no deposit, no appointment scheduled — the software records an acceptance. The actual rate of treatment that gets completed is a different number entirely. We have seen practices report 77% case acceptance in their prospectus materials while the raw PMS data shows 41%. That gap is not a rounding error. It is a structural flaw in the business.

The Fee Schedule Cliff: If the seller holds Delta Premier status and you do not, you are not inheriting their fee schedule. You are inheriting a patient base that will be billed at a significantly lower reimbursement rate the moment the transition is complete. That is not a negotiating point. It is a financial reality that needs to be modeled before you sign the LOI, not discovered after you close.

---

Looking for Opportunity, Not Just Risk

There is a misconception that a deep, forensic evaluation of a practice is inherently adversarial. That if you start pulling raw data from the practice management software, you are trying to tear the deal apart.

That is the wrong lens.

A true evaluation isn’t just about finding risk. It is about finding opportunity.

When we evaluate a practice, we aren’t just looking for inflated active patient counts or bloated operational expenses. We are looking for the value gaps — the places where the practice is underperforming relative to what it could be in the right hands.

If a practice is generating $1 million in revenue but has weak case acceptance and an underdeveloped periodontal program, that isn’t just a red flag. In the right hands, with the right operational systems, that is a $1.7 million practice waiting to be unlocked.

But you can only unlock that value if you know it exists. If you buy the practice based on the seller’s narrative, you will likely continue running it the way the seller ran it. If you buy the practice based on the data, you walk in on Day 1 with an operational roadmap — a clear picture of where the revenue is, where it isn’t, and exactly what needs to change.

---

The Question Every New Owner Asks

There is a question that lives in the back of every first-time buyer’s mind, even if they don’t say it out loud: Can I fill their shoes?

It is a legitimate question. Provider concentration — the percentage of total production tied to the selling doctor — is one of the most scrutinized metrics in any practice evaluation. A practice where the seller generates 65% of total production is not unusual. But the incoming buyer has to be able to keep pace. Not just clinically, but philosophically. They have to treatment plan at a similar level. They have to diagnose with similar confidence. They have to present treatment in a way that earns the same level of patient trust.

I worked with a buyer who purchased a practice that, during the evaluation, showed an average treatment plan of $2,600. That is a high number for a general practice. It tells you something specific about the selling doctor — they diagnosed comprehensively, presented confidently, and had built a patient base that accepted that level of care. The data was transparent. The buyer saw the number before he signed.

He wasn’t in the practice two weeks before he was taking a tomahawk to treatment plans. His average came in around $900 — a below-average number for a general practice, and a dramatic departure from the clinical philosophy that had built the revenue he just paid for.

Despite the transparency of the evaluation, he was floundering.

The data told him what the practice was. It could not tell him whether he was the right buyer for it. That is a question only he could answer honestly — and he didn’t.

This is the part of due diligence that no report can fully capture. The evaluation tells you the average treatment plan, the case acceptance rate, the clinical production mix. What it cannot do is assess the gap between the seller’s clinical philosophy and yours. That gap is your responsibility to close before you sign — not after.

A $2,600 average treatment plan practice in the hands of a $900 diagnoser is not a $1.7 million opportunity. It is a $1.2 million practice on its way to becoming something much smaller.

---

Day 1 Clarity

The difference between a buyer who does the forensic work and a buyer who doesn’t becomes obvious the moment the keys change hands.

The buyer who skipped due diligence spends their first 90 days reacting. They are surprised by the fee schedule cliff. They are surprised by the team culture that the seller had been managing through sheer force of personality. They are surprised that the revenue was attached to the seller’s hands — not to the systems, not to the patient base — and that when the seller left, a meaningful portion of the production left with them.

Every surprise costs money.

Some of them cost more than that.

The buyer who did the work spends their first 90 days executing.

They already know the case acceptance baseline and have a plan to move it. They already know the fee schedule exposure and have modeled the cash reserve they need to bridge the credentialing gap. They already know exactly where the operational leaks are, and they have a plan to plug them before those leaks become losses.

They don’t feel the suffocating pressure of the unknown. They only feel the manageable friction of execution.

The broker who looked at our evaluation understood this immediately. He had seen what buyers typically walk into. He had seen the surprises, the regret, the practices that should have sold but didn’t because nobody built the story the data needed to tell.

This was different. This buyer knew exactly what they were walking into.

That is what preparation looks like. And in a market where the vast majority of practice sales still happen without it, preparation is the most significant competitive advantage a buyer can have.